• Filter By:
• Specialty
• Source
• Condition
• Cancer
• Infectious Disease
• Drug
• Training
• Management
• Procedure
• Therapy
• Vaccine
• Nutrition
• Country

Which is first? Whether Takotsubo cardiomyopathy was complicated with acute stroke or acute stroke caused Takotsubo cardiomyopathy? A case report.
PMID: 25163080 [PubMed - as supplied by publisher]
Source: The Anatolian Journal of Cardiology - August 22, 2014 Category: Cardiology Authors: Akyüz AR, Korkmaz L, Turan T, Varlıbaş A Tags: Anadolu Kardiyol Derg Source Type: research

Myocardial fibrosis in stroke survivors
Stroke survivors are most likely to die of cardiac death, yet few undergo comprehensive cardiac assessment to look for reversible causes. Myocardial fibrosis (MF) is not only the hallmark of cardiomyopathy, but also a substrate for sudden cardiac death, ventricular tachyarrhythmia and heart failure. Procollagen carboxyl-terminal telopeptide (PICP) was found to be a marker of MF. The relationship between PICP and cardiac abnormalities in stroke survivors is unknown. We recently showed that MF in stroke survivors can be treated by spironolactone and amiloride in a randomised placebo-controlled cross-over study with reduction...
Source: International Journal of Cardiology - March 19, 2015 Category: Cardiology Authors: K. Wong, S. Sze, S. Wong, S. McSwiggan, V. Allgar, R. MacWalter, A.D. Struthers Tags: Letter to editor Source Type: research

Incidence of ischemic stroke and systemic embolism in patients with hypertrophic cardiomyopathy, nonvalvular atrial fibrillation, CHA 2 DS 2 -VASc score of ≤1 and without anticoagulant therapy
Abstract Data on the risk of ischemic stroke and systemic embolism (iSSE) events in patients with nonvalvular atrial fibrillation (NVAF), a CHA2DS2-VASc score of ≤1, hypertrophic cardiomyopathy (HCM), and without anticoagulant therapy are still lacking. The aim of this study was to investigate the incidence of iSSE events in these patients. We consecutively screened medical records of patients with HCM and NVAF referred to Fuwai Hospital between January 1994 and March 2014. The primary end point was iSSE events, defined as a composite of ischemic stroke and systemic embolism. Follow-up was carried out to ascert...
Source: Heart and Vessels - July 31, 2015 Category: Cardiology Source Type: research

The Indian consensus guidance on stroke prevention in atrial fibrillation: An emphasis on practical use of nonvitamin K oral anticoagulants.
Abstract The last ten years have seen rapid strides in the evolution of nonvitamin K oral anticoagulants (NOACs) for stroke prevention in patients with atrial fibrillation (AF). For the preparation of this consensus, a comprehensive literature search was performed and data on available trials, subpopulation analyses, and case reports were analyzed. This Indian consensus document intends to provide guidance on selecting the right NOAC for the right patients by formulating expert opinions based on the available trials and Asian/Indian subpopulation analyses of these trials. A section has been dedicated to the curren...
Source: Indian Heart J - December 1, 2015 Category: Cardiology Authors: Dalal J, Bhave A, Oomman A, Vora A, Saxena A, Kahali D, Poncha F, Gambhir DS, Chaudhuri JR, Sinha N, Ray S, Iyengar SS, Banerjee S, Kaul U, SPAF Academy India experts Tags: Indian Heart J Source Type: research

Author's reply to Atrial fibrillation patients with hypertrophic cardiomyopathy: Do we need new stroke risk stratification?
We thank Dr. Joung and colleagues for their interests in our work.1 In our study, patients with non-valvular atrial fibrillation (NVAF) with hypertrophic cardiomyopathy (HCM) had a higher risk of stroke than NVAF patients without HCM in all generations and all CHA2DS2-VASc score groups. As shown in the study of Jung et al.,2 the stroke risk in NVAF with HCM without any other stroke risk factor was greater than that in NVAF with a CHA2DS2-VASc score of 2. We agree with their results, and all NVAF patients with HCM should receive anticoagulation.
Source: Heart Rhythm - April 3, 2019 Category: Cardiology Authors: Toyonobu Tsuda, Akihiro Nomura, Kenshi Hayashi Source Type: research

Reply to the Editor — Patients with atrial fibrillation with hypertrophic cardiomyopathy: Do we need new stroke risk stratification?
We thank Joung et  al for their interest in our work.1 In our study, patients with nonvalvular atrial fibrillation (NVAF) with hypertrophic cardiomyopathy (HCM) had a higher risk of stroke than did patients with NVAF without HCM in all generations and all CHA2DS2-VASc score groups. As shown in the study by Jung et  al,2 stroke risk in patients with NVAF with HCM without any other stroke risk factor was higher than that in patients with NVAF with a CHA2DS2-VASc score of 2. We agree with their results, and all patients with NVAF with HCM should receive anticoagulation.
Source: Heart Rhythm - April 3, 2019 Category: Cardiology Authors: Toyonobu Tsuda, Akihiro Nomura, Kenshi Hayashi Source Type: research

Stroke and Bleeding Risk Assessment in Atrial Fibrillation: Where Are We Now?
Korean Circ J. 2021 Jun 1. doi: 10.4070/kcj.2021.0170. Online ahead of print.ABSTRACTMost important international guidelines recommend the use of CHA₂DS₂-VASc and HAS-BLED scores for stroke and bleeding risk assessments in atrial fibrillation (AF) patients, respectively. The 2020 AF guidelines of European Society of Cardiology have revised the definition of "C: congestive heart failure (HF)" component, and now patients with either HF with reduced ejection fraction or preserved ejection fraction should be assigned 1 point. Hypertrophic cardiomyopathy was also included. Besides, the revised "V: vascular diseases" compone...
Source: Korean Circulation Journal - July 6, 2021 Category: Cardiology Authors: Ling Kuo Yi Hsin Chan Jo Nan Liao Shih Ann Chen Tze Fan Chao Source Type: research

Pages: 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20